Kelyniam Global Announces Strong Q1 2026 Financial Results
Rhea-AI Summary
Kelyniam Global (OTC: KLYG) reported strong Q1 2026 results, with clear year-over-year growth and improved profitability.
- Revenue rose 84% to $1,150,130.
- Gross profit increased 105% to $962,814.
- Income from operations reached $295,295 versus a prior loss.
CustomizedBone™ implant sales grew over 50%, the first Fusion PEEK + BCP implant was placed, and a consulting/development agreement generated significant one-time revenue.
Positive
- Total revenue up 84% year-over-year to $1,150,130
- Gross profit up 105% year-over-year to $962,814
- Operating result improved to $295,295 from a $(140,556) loss
- CustomizedBone™ implant sales grew more than 50% year-over-year
- First Fusion PEEK + Bicalcium Phosphate implant successfully implanted
- Exclusive U.S. marketing rights for PEEK+BCP implant through March 2028
- Consulting and development agreement generated significant one-time revenue
Negative
- Q1 2026 results were boosted by significant one-time consulting revenue
News Market Reaction – KLYG
In the May 11 session, KLYG gained 76.80%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Q1 Financial Highlights (Compared to Q1 2025)
- Total revenue reached
$1,150,130 84% increase from$624,910 - Gross profit rose to
$962,814 $470,490 105% increase. - Income from operations improved to
$295,295 $(140,556)
"We are very pleased with our strong start in 2026," said Ross Bjella, CEO. "These results reflect the hard work of our team and the growing demand for our regenerative product line."
Sales of CustomizedBone™ implants, licensed from Finceramica, grew more than
In addition, a surgeon successfully implanted the first Fusion PEEK + Bicalcium Phosphate (BCP) implant during the quarter. This innovative implant combines the strength of PEEK with the bone-integration properties of BCP. Both PEEK implants can be delivered overnight and can include Kelyniam's patented integrated fixation system. Kelyniam holds the exclusive right to market the PEEK+BCP implant in
The company also entered into a consulting and development agreement with another medical device company in early Q1. This agreement brought in significant one-time revenue that helped boost results for the quarter. Kelyniam is recognized as a strong partner for medical device companies that want to enter the
About Kelyniam Global Kelyniam Global, Inc. specializes in the rapid production of custom prosthetic cranial implants using computer-aided design and computer-aided manufacturing of advanced medical-grade polymers. The company develops, manufactures, and distributes custom cranial and craniofacial implants for patients who need reconstruction. Kelyniam works closely with surgeons, health systems, and payors to support positive clinical and cost-of-care outcomes. For more information, visit www.Kelyniam.com.
Cautionary Note Regarding Forward-Looking Statements As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially from those projected. These risks include changes in economic conditions, competitive factors, the company's ability to execute its plans, regulatory developments, and other risks described from time to time in the company's SEC reports.
View original content:https://www.prnewswire.com/news-releases/kelyniam-global-announces-strong-q1-2026-financial-results-302767772.html
SOURCE Kelyniam Global Inc